Drug Profile
Research programme: alfa synuclein targeted positron emission tomography imaging tracers - APRINOIA Therapeutics
Alternative Names: α-Syn PET tracerLatest Information Update: 07 Jul 2022
Price :
$50
*
At a glance
- Originator APRINOIA Therapeutics
- Class Diagnostic agents; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Multiple system atrophy; Parkinson's disease
Most Recent Events
- 07 Jul 2022 Preclinical trials in Multiple system atrophy (Diagnosis) in Taiwan (Parenteral) (APRINOIA Therapeutics pipeline, July 2022)
- 07 Jul 2022 Preclinical trials in Parkinson's disease (Diagnosis) in Taiwan (Parenteral) (APRINOIA Therapeutics pipeline, July 2022)
- 29 Dec 2020 APRINOIA Therapeutics in-licenses AI-powered system from InSilico Medicine